Tribune News Service
New Delhi, January 30
Serum Institute today said it had applied to the Drug Controller General of India for permission to start local trials of a new Covid-19 vaccine the country is developing in collaboration with American firm Novovax. The vaccine has been shown to be 89.3 per cent effective in UK trials.
Serum Institute CEO Adar Poonawala said: “Our partnership for a Covid vaccine with Novovax has published excellent efficacy results. We have applied to start trials in India. Hope to launch Covovax by June this year.”
In a related development, American healthcare giant Johnson & Johnson said its Covid-19 vaccine candidate was 66 per cent effective overall in preventing moderate to severe Covid, 28 days after inoculation. The result was based on Phase-3 study involving nearly 44,000 participants.
Meanwhile, one year since it reported the first Covid case on January 30 last year, India has registered the highest recoveries at 96.98 per cent. Total active caseload has dropped to less than 1.7 lakh (1,69,824) today and only 1.58 per cent of the infected people are currently under treatment. Twenty seven states and UTs have weekly positivity rate less than the national average.
35L vaccinated so far
Over 35 lakh beneficiaries were vaccinated till Saturday morning under the countrywide exercise. In the last 24 hours, 5,71,974 people were vaccinated across 10,809 sessions.